ProfileGDS5678 / 1437711_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 98% 98% 97% 96% 97% 95% 94% 94% 93% 99% 99% 99% 99% 99% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 19.9349598
GSM967853U87-EV human glioblastoma xenograft - Control 29.9723798
GSM967854U87-EV human glioblastoma xenograft - Control 39.6352397
GSM967855U87-EV human glioblastoma xenograft - Control 48.9194896
GSM967856U87-EV human glioblastoma xenograft - Control 59.4699597
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.1568795
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.0541394
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.0045994
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.9135493
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 111.365699
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 211.718899
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 311.329799
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 410.957499
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 510.978799